These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39042829)

  • 1. Targeted Radionuclide Therapy in Glioblastoma.
    Zhao X; Jakobsson V; Tao Y; Zhao T; Wang J; Khong PL; Chen X; Zhang J
    ACS Appl Mater Interfaces; 2024 Aug; 16(31):40391-40410. PubMed ID: 39042829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL13RA2 targeted alpha particle therapy against glioblastomas.
    Sattiraju A; Solingapuram Sai KK; Xuan A; Pandya DN; Almaguel FG; Wadas TJ; Herpai DM; Debinski W; Mintz A
    Oncotarget; 2017 Jun; 8(26):42997-43007. PubMed ID: 28562337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in targeted drug delivery for the treatment of glioblastoma.
    Mao M; Wu Y; He Q
    Nanoscale; 2024 May; 16(18):8689-8707. PubMed ID: 38606460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional Confinement and Major Clinical Benefit of
    Séhédic D; Chourpa I; Tétaud C; Griveau A; Loussouarn C; Avril S; Legendre C; Lepareur N; Wion D; Hindré F; Davodeau F; Garcion E
    Theranostics; 2017; 7(18):4517-4536. PubMed ID: 29158842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Orthotopic U251 Human Glioblastoma Multiforme Tumors in NRG Mice by Convection-Enhanced Delivery of Gold Nanoparticles Labeled with the β-Particle-Emitting Radionuclide,
    Georgiou CJ; Cai Z; Alsaden N; Cho H; Behboudi M; Winnik MA; Rutka JT; Reilly RM
    Mol Pharm; 2023 Jan; 20(1):582-592. PubMed ID: 36516432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.
    Bolcaen J; Kleynhans J; Nair S; Verhoeven J; Goethals I; Sathekge M; Vandevoorde C; Ebenhan T
    Theranostics; 2021; 11(16):7911-7947. PubMed ID: 34335972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.
    Behling K; Maguire WF; López Puebla JC; Sprinkle SR; Ruggiero A; O'Donoghue J; Gutin PH; Scheinberg DA; McDevitt MR
    J Nucl Med; 2016 Oct; 57(10):1576-1582. PubMed ID: 27127217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools.
    Cela I; Capone E; Trevisi G; Sala G
    Semin Cancer Biol; 2024 Jun; 101():25-43. PubMed ID: 38754752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Development of Glioblastoma Therapeutic Agents.
    Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
    Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations.
    Filosofov D; Kurakina E; Radchenko V
    Nucl Med Biol; 2021; 94-95():1-19. PubMed ID: 33461040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma.
    Branco F; Cunha J; Mendes M; Vitorino C; Sousa JJ
    ACS Nano; 2024 Jul; 18(26):16359-16394. PubMed ID: 38861272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Vascular Drug Delivery in Cerebral Cancer.
    Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
    Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.
    Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH
    ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint-Blocking Nanocages Cross the Blood-Brain Barrier and Impede Brain Tumor Growth.
    Kim M; Yoon HJ; Lee C; Lee M; Park RW; Lee B; Park EJ; Kim S
    ACS Biomater Sci Eng; 2024 Jan; 10(1):575-587. PubMed ID: 38150627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring therapeutic monoclonal antibodies in brain tumor.
    Ait-Belkacem R; Berenguer C; Villard C; Ouafik L; Figarella-Branger D; Beck A; Chinot O; Lafitte D
    MAbs; 2014; 6(6):1385-93. PubMed ID: 25484065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomaterials and 3D Bioprinting Strategies to Model Glioblastoma and the Blood-Brain Barrier.
    Tang M; Rich JN; Chen S
    Adv Mater; 2021 Feb; 33(5):e2004776. PubMed ID: 33326131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
    Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
    AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.